We’re AbbVie’s corporate strategic venture capital arm
Investing since 2009, we focus exclusively on novel, transformational
therapeutics at discovery and pre-clinical stages. Aligning with
AbbVie’s strategic focus, our investments address critical needs in
oncology, immunology, and neuroscience. We offer our partners access
to AbbVie’s vast internal network of experts in all phases of drug
development, from drug discovery through successful
commercialization.
Our current portfolio is comprised of over 20 companies based in the US and Europe. Targeting six to eight new investments annually, predominantly at the Seed or Series A stage, we have the capability and flexibility to lead or co-lead a syndicate. Our team of seven investing professionals is based in three locations: Boston, San Francisco and Chicago areas.